The Long Game
The Signal: New guidelines that could redefine who gets treated for cardiovascular disease
The American College of Cardiology and the American Heart Association released an updated guideline for managing dyslipidemia this past Thursday American Heart Association, the first major overhaul of the nation's cholesterol standards since 2018. The guidelines call for all adults to be tested once for lipoprotein(a), a genetic marker for heart disease, and recommend wider use of coronary calcium scoring and a new risk calculator that projects cardiovascular risk over both 10 and 30 years. NPR The new guidelines also adjust the threshold for when doctors should recommend lifestyle intervention or medication downward, and begin risk conversations as early as age 30. Statnews Cardiologists are calling this a sea change in preventive medicine, and the volume of coverage suggests the general public is paying attention. Here's what people are reacting to.
The Noise
The story most people are reading is: "you might need a statin sooner." That's not wrong, exactly, but it's the least interesting part of what happened. The guidelines now formally recognize that ApoB, the measure of actual plaque-building particles in your blood, gives a clearer cardiovascular risk picture than standard LDL in people with diabetes or high triglycerides California Today, and almost nobody is talking about that. The headline coverage is focused on medication thresholds because statins are a familiar hook. The deeper signal, that cardiovascular risk is a longitudinal story your biomarkers tell over decades, is getting buried.
The Long Game Lens
What the new guidelines are actually codifying is something longitudinal thinkers have understood for years: cardiovascular risk is not an event, it is a trajectory. Leading cardiologists are now explicitly framing time-averaged LDL over a lifetime as one of the strongest predictors of cardiovascular disease, TCTMD which means the window for meaningful intervention is your 30s and 40s, not after a first cardiac event. The formal elevation of ApoB and Lp(a) as clinical tools reflects the evolving understanding that atherogenic risk goes beyond LDL particles alone. American Heart Association The metabolic and inflammatory systems that drive this process are the same ones shaped by nutrition quality, sleep, movement patterns, and stress regulation. Every year you spend with unaddressed inflammation or insulin resistance is a year your arteries are accumulating damage that no single biomarker snapshot will catch. The question is never whether your cholesterol is high right now. The question is what direction your biology is moving, and how fast. That's the game ResetRx is built to play.
The Monday Morning Reset
This Week's Reset: Get an ApoB test added to your next routine blood draw, then log the result alongside your most recent LDL reading.
Why This Works Micro-science
ApoB measures the number of lipoprotein particles carrying cholesterol into arterial walls, which predicts cardiovascular risk independently of LDL in people with metabolic dysfunction, insulin resistance, or normal-looking cholesterol panels. Normal LDL does not automatically mean low risk, Parriva and ApoB is the biomarker that surfaces that gap. Tracking both gives you a more complete signal about your long-term cardiovascular trajectory than either number alone. [Blumenthal et al., JACC/Circulation, 2026]